Philip Morris International (PM) is trading up at $201.26 (+0.10%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Consumer Staples sector.
One firm's current price target on Philip Morris International: $225 — 12% above the current $201. Each is tracked to its date and scored the same way a member's call is.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $75.0B | $78.1B | $29.6B | $29.8B | $28.7B | $31.4B | $31.8B | $35.2B | $37.9B | $40.6B |
| Growth (year over year) | +1.4% | +4.2% | −62.1% | +0.6% | −3.7% | +9.4% | +1.1% | +10.7% | +7.7% | +7.3% |
| Gross profit | $17.3B | $18.3B | $18.9B | $19.3B | $19.1B | $21.4B | $20.4B | $22.3B | $24.5B | $27.3B |
| Gross margin | 23.1% | 23.5% | 63.7% | 64.7% | 66.7% | 68.1% | 64.1% | 63.3% | 64.8% | 67.1% |
| Operating income | $10.9B | $11.6B | $11.4B | $10.5B | $11.7B | $13.0B | $12.2B | $11.6B | $13.4B | $14.9B |
| Operating margin | 14.5% | 14.8% | 38.4% | 35.3% | 40.7% | 41.3% | 38.6% | 32.9% | 35.4% | 36.6% |
| Net income | $6.97B | $6.04B | $7.91B | $7.18B | $8.06B | $9.11B | $9.05B | $7.81B | $7.06B | $11.3B |
| Net margin | 9.3% | 7.7% | 26.7% | 24.1% | 28.1% | 29.0% | 28.5% | 22.2% | 18.6% | 27.9% |
| EPS (diluted) | $4.48 | $3.88 | $5.08 | $4.61 | $5.16 | $5.83 | $5.81 | $5.02 | $4.52 | $7.26 |
| Balance sheet | ||||||||||
| Cash and equivalents | $4.24B | $8.45B | $6.59B | $6.86B | $7.28B | $4.50B | $3.21B | $3.06B | $4.22B | $4.87B |
| Total assets | $36.9B | $43.0B | $39.8B | $42.9B | $44.8B | $41.3B | $61.7B | $65.3B | $61.8B | $69.2B |
| Total liabilities | $47.8B | $53.2B | $50.5B | $52.5B | $55.4B | $49.5B | $68.0B | $74.8B | $71.7B | $77.2B |
| Long-term debt | $25.9B | $31.3B | $27.0B | $26.7B | $28.2B | $24.8B | $34.9B | $41.2B | $42.2B | $45.1B |
| Shareholders' equity | −$12.7B | −$12.1B | −$12.5B | −$11.6B | −$12.6B | −$10.1B | −$8.96B | −$11.2B | −$11.8B | −$9.99B |
| Cash flow | ||||||||||
| Operating cash flow | $8.08B | $8.91B | $9.48B | $10.1B | $9.81B | $12.0B | $10.8B | $9.20B | $12.2B | $12.2B |
| Capital expenditure | $1.17B | $1.55B | $1.44B | $852.0M | $602.0M | $748.0M | $1.08B | $1.32B | $1.44B | $1.57B |
| Free cash flow | $6.91B | $7.36B | $8.04B | $9.24B | $9.21B | $11.2B | $9.73B | $7.88B | $10.8B | $10.7B |
| Dividends paid | $6.38B | $6.52B | $6.88B | $7.16B | $7.36B | $7.58B | $7.81B | $7.96B | $8.20B | $8.62B |
| Share buybacks | $0 | $0 | — | $0 | $0 | $775.0M | $209.0M | $0 | $0 | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.91B | $9.71B | $9.30B | $10.1B | $10.8B | $10.4B | $10.1B | $11.2B |
| Growth (year over year) | +8.4% | +7.3% | +5.8% | +7.1% | +9.4% | +6.8% | +9.1% | +10.4% |
| Gross profit | $6.54B | $6.28B | $6.27B | $6.87B | $7.36B | $6.79B | $6.91B | $7.66B |
| Gross margin | 66.0% | 64.7% | 67.4% | 67.7% | 67.8% | 65.5% | 68.1% | 68.4% |
| Operating income | $3.65B | $3.26B | $3.54B | $3.71B | $4.26B | $3.37B | $3.89B | $4.53B |
| Operating margin | 36.9% | 33.6% | 38.1% | 36.6% | 39.3% | 32.6% | 38.4% | 40.5% |
| Net income | $3.08B | −$579.0M | $2.69B | $3.04B | $3.48B | $2.14B | $2.44B | $2.82B |
| Net margin | 31.1% | −6.0% | 28.9% | 30.0% | 32.1% | 20.7% | 24.0% | 25.2% |
| EPS (diluted) | $1.97 | −$0.37 | $1.72 | $1.95 | $2.23 | $1.36 | $1.56 | $1.80 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.26B | $4.22B | $4.44B | $4.14B | $4.04B | $4.87B | $5.45B | $6.00B |
| Total assets | $66.9B | $61.8B | $65.1B | $68.5B | $67.1B | $69.2B | $68.9B | $68.3B |
| Total liabilities | $74.6B | $71.7B | $74.0B | $78.5B | $76.0B | $77.2B | $76.2B | $74.9B |
| Long-term debt | $44.2B | $42.2B | $38.8B | $42.4B | $41.9B | $45.1B | $43.8B | $42.4B |
| Shareholders' equity | −$9.69B | −$11.8B | −$10.9B | −$12.0B | −$10.9B | −$9.99B | −$9.28B | −$8.58B |
| Cash flow | ||||||||
| Operating cash flow | $3.34B | $4.00B | −$350.0M | $3.41B | $4.46B | $4.71B | −$399.0M | $5.49B |
| Capital expenditure | $379.0M | $278.0M | $404.0M | $356.0M | $365.0M | $444.0M | $353.0M | $380.0M |
| Free cash flow | $2.96B | $3.72B | −$754.0M | $3.06B | $4.10B | $4.26B | −$752.0M | $5.11B |
| Dividends paid | $2.03B | $2.11B | $2.12B | $2.11B | $2.11B | $2.29B | $2.31B | $2.30B |
From Philip Morris International's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Philip Morris International's latest reported figures next to the median of the other 33 S&P 500 Consumer Staples companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Philip Morris International | Consumer Staples (33 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +7.3% | +2.1% | +7.0% |
| Net margin, latest fiscal year | 27.9% | 6.4% | 12.9% |
| Dividend per share, latest fiscal year | $5.64 | $2.04 | $2.40 |
| Share price change, 1 year | +27.2% | +4.9% | +5.6% |
Philip Morris International: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Philip Morris International included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 31/496, net margin 31/496, dividend per share 25/349, 1-year price change 32/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 25 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
Philip Morris International Inc. (PMI) is a American publicly traded tobacco company, with products sold in over 180 countries. Marlboro is PMI’s most recognized brand, but in the last quarter of 2023, Iqos generated the greatest revenue. Philip Morris International is often referred to as one of the companies comprising Big Tobacco. The company ranked No. 117 in the 2025 Fortune 500 list of the largest US corporations by total revenue.
Source: Wikipedia — Philip Morris International
Intel, Philip Morris among market cap stock movers on Thursday
Intel, Philip Morris among market cap stock movers on Thursday
Philip Morris’ Dividend Gets an 8.8% Boost: What Investors Should Know
Philip Morris’ Dividend Gets an 8.8% Boost: What Investors Should Know
Philip Morris raises quarterly dividend 8.8% to $1.60 per share
Philip Morris raises quarterly dividend 8.8% to $1.60 per share
Philip Morris Raises FX Outlook as IQOS, ZYN Fuel Smoke-Free Growth
Philip Morris Raises FX Outlook as IQOS, ZYN Fuel Smoke-Free Growth
FDA Authorization Expands Philip Morris’s Zyn Bet, Can It Pay Off?
FDA Authorization Expands Philip Morris’s Zyn Bet, Can It Pay Off?
I've Been Wrong About Philip Morris International Stock for 5 Years. Here's Why I'm Finally Changing My Mind.
I've Been Wrong About Philip Morris International Stock for 5 Years. Here's Why I'm Finally Changing My Mind.
Altria vs. Philip Morris: What the New Manufacturing Deal Means for Investors
Altria vs. Philip Morris: What the New Manufacturing Deal Means for Investors
Altria, Philip Morris International sign contract manufacturing deals
Altria, Philip Morris International sign contract manufacturing deals